Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors

Harbinder Singh | Devendra K. Agrawal

Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California, USA

Correspondence
Devendra K. Agrawal, Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, 309 E. Second St, Pomona, CA 91766-1854, USA.
Email: DAgrawal@WesternU.edu

Funding information
National Institutes of Health, Grant/Award Numbers: R01 HL144125, R01 HL147662

Abstract
Receptor for advanced glycation end products (RAGE) is a 45 kDa transmembrane receptor of immunoglobulin family that can bind to various endogenous and exogenous ligands and initiate the inflammatory downstream signaling pathways. RAGE is involved in various disorders including cardiovascular and neurodegenerative diseases, cancer, and diabetes. This review summarizes the structural features of RAGE and its various isoforms along with their pathological effects. Mainly, the article emphasized on the translational significance of antagonizing the interactions of RAGE with its ligands using small molecules reported in the last 5 years and discusses future approaches that could be employed to block the interactions in the treatment of chronic inflammatory ailments. The RAGE inhibitors described in this article could prove as a powerful approach in the management of immune-inflammatory diseases. A critical review of the literature suggests that there is a dire need to dive deeper into the molecular mechanism of action to resolve critical issues that must be addressed to understand RAGE-targeting therapy and long-term blockade of RAGE in human diseases.

KEYWORDS
AGEs, antagonist, chronic inflammatory diseases, endogenous ligands, exogenous ligands, inhibitor, RAGE, RAGE isoforms, S100 proteins

1 | INTRODUCTION

Various sugar molecules, such as glycoaldehyde, glucose, and fructose, nonenzymatically can react with amine-based macromolecules such as proteins, nucleic acids, and lipids to produce reversible Schiff bases. These Schiff bases further undergo various complex reactions like rearrangement, dehydration, and condensation to form irreversible adduct known as advanced glycation end products (AGEs) (Akkhter et al., 2015; Jabir et al., 2018; Yamagishi, 2011). Nonenzymatic glycation of macromolecules alters their physiological function and structural integrity that ultimately leads to loss of enzymatic function, protein aggregation, and cross-linking (Adrover et al., 2014; Li et al., 2012; Nenna et al., 2015; Sajithial et al., 1998; Vistoli et al., 2013). The accumulation of the advanced glycation products (AGEs) plays a significant role in many inflammatory health disorders including cardiovascular, diabetes mellitus, immune-inflammation, cancer, and neurodegenerative disorders (Li et al., 2012; Logsdon et al., 2007; Nenna et al., 2015; Ramasamy et al., 2005; Ray et al., 2016; Sparvero et al., 2009). Functionally, AGEs are recognized by the cell surface receptor of immunoglobulin superfamily called as receptor for advanced glycation end products (RAGE). RAGE is a 45 kDa transmembrane receptor that is present in very low...
concentration in healthy human tissues such as liver, kidneys, lungs, brain, cardiovascular, and immune systems (Cheng et al., 2005; Neepet al., 1992). In addition to AGEs, RAGE can interact with a number of endogenous ligands including S100/calgranulin proteins, HMGB1 (high mobility group box-1), Aβ1-42–peptides (amyloid-β), and exogenous ligand, LPS (lipopolysaccharides) (Chavakis et al., 2003; Fritz, 2011; Hudson & Lippman, 2018). As a receptor for these ligands, RAGE itself has been considered as a potential biomarker for various pathological conditions like cardiovascular diseases, diabetes mellitus, diabetic nephropathy, cancer, and Alzheimer’s disease (Deane et al., 2012; Logsdon et al., 2007; Nabi et al., 2019; Nasser et al., 2015; Ramasamy et al., 2005; Ray et al., 2016; Riehl et al., 2009; Tabrez et al., 2015). The overall mechanisms of glycation to produce AGEs and various ligand binding with RAGE to overexpress the inflammatory cytokines are depicted in Figure 1a,b, respectively.

Expression of RAGE has been found in many embryonic tissues but its expression decreases in adult tissues, except lung and skin (Bierhaus et al., 2005). Its high expression has been found in basolateral membrane of epithelial cells AT-1, and AT-2 cells, alveolar macrophages, and bronchiolar epithelia (Katsukawa et al., 1997; Oczypok et al., 2017). Under inflammatory conditions, RAGE expression is significantly upregulated in neuronal cells, vascular smooth muscle cells (VSMCs), endothelial cells (ECs), airway smooth muscle cells, pericytes, and in circulating eosinophils, dendritic cells, macrophages, T cells, and B cells (Bierhaus et al., 2005; Brett et al., 1993; Chua et al., 2013; Hudson & Lippman, 2018; Lin et al., 2009; Yonekura et al., 2003).

Structurally, full-length human RAGE is a 45 kDa protein that consists of three major domains: First, the extracellular domain with 23–342 amino acid residues, second is hydrophobic transmembrane domain with 343–363 amino acid residues, and third one is intracellular cytoplasmic domain with 464–404 residues (UniProtBeta, 2022) (Figure 2). An extracellular region further subdivided into three immunoglobulin like domains named: Variable domain (V-domain) having 23–116 amino acid residues which is connected to two constant domains C1 (residues 124–221) and C2 (residues 227–317). Various strands present in the V-domain of RAGE are connected

**FIGURE 1** (a) Mechanisms of glycation to produce AGEs and (b) Ligand binding with RAGE and the downstream signaling pathways. AGEs, advanced glycation end products; RAGE, receptor for advanced glycation end products
through two β-sheets which are linked together by a disulfide bridge between two cysteine amino acid residues (Cys38 and Cys99) (Xue et al., 2011; Yatime & Andersen, 2013) (Figure 2). The surface around V-domain and C1 domain is covered by a large positively charged area and a hydrophobic cavity. Various studies demonstrated that the integrated structural unit of V and C1 domain is primarily responsible for the interactions with a diverse group of RAGE ligands of negatively charged molecules, including S100/calgranulins, AGEs, HMGB1, and Aβ-proteins to exert their specific effects (Dattilo et al., 2007; Hori et al., 1995; Koch et al., 2010; Sturchler et al., 2008; Xue et al., 2011, 2014).

Due to the lack of sufficient data on the transmembrane domain of RAGE (residues 343–363), little is known, so far, about its structure and functions. However, it induces signal transduction probably due to the helix-helix homodimerization of the receptor (Sturchler et al., 2008).

The cytoplasmic domain of RAGE (residues 364–404) also has three regions: a 17-amino acid domain known as membrane-proximal domain, this is further connected to central 17-amino acid domain, and C-terminal domain. These domains also perform crucial interactions with various downstream signaling effector molecules such as Toll-interleukin 1 receptor domain adaptor protein (TIRAP), diaphanous related formin-1 (DIAPH1), and extracellular signal-regulated kinases 1 and 2 (ERK1/2) that ultimately lead to the activation of mitogen-activated protein kinase (MAPK) pathway (Hudson et al., 2008; Ishihara et al., 2003; Rai et al., 2012). This domain of human RAGE also shares 92% and 70% sequence identity with primates and rodents, respectively (Rodriguez Gonzalez-Moro et al., 2009).
According to the alternative splicing and metalloproteinase-regulated cleavage, RAGE can exist as multiple variants with different binding partners and can perform diverse biological functions (Jules et al., 2013; Zhang et al., 2008). Figure 2 represents the full-length RAGE and its various isoforms with their amino acid sequence length. The full-length RAGE consists of all key constituents with amino acid sequence of 23–404 residues and can perform a key role in diverse downstream signaling pathways that can affect inflammatory responses, oxidative stress, cellular proliferation, migration, and apoptosis (Hong et al., 2016; Hudson et al., 2008; Jules et al., 2013). Deletion of cytoplasmic all key constituents with amino acid sequence of 23–363 which shows dominant-negative effect with reduced signaling response to RAGE ligands (Kosaka et al., 2014) (Figure 2). The overexpression of DN-RAGE can attenuate the cancer cell proliferation and invasion in vitro and in vivo experiments (Takeuchi et al., 2013). Similarly, lacking the N-terminal variable domain (V-domain) in N-RAGE (residues 124–404) diminished its ability to bind with various ligands that can bind to this domain. However, N-RAGE can exhibit its V-domain-independent pathological functions and signal transduction (Yonekura et al., 2003). Further, the cleavage of the extracellular domain from the cell surface via metalloproteinases produce soluble form of RAGE (sRAGE; residues 23–342) which is the dominant form counteracting the RAGE-mediated functions by acting as its decoy receptor (Emanuele et al., 2005; Falcone et al., 2005; Kalea et al., 2009; Scavello et al., 2021). The direct administration of sRAGE in vivo has been shown to reverse the RAGE-mediated pathological conditions (Cho et al., 2009; Geroldi et al., 2006; Kalea et al., 2009; Scavello et al., 2021).

2 | LIGANDS THAT CAN BIND TO RAGE

Due to the presence of various domains (V, C1, and C2) on RAGE, it can bind to the diverse classes of ligands, including AGEs, S100 calcium-binding proteins, amyloid-β, HMGB1, and so forth (Chavakis et al., 2003; Hofmann et al., 1999; Hori et al., 1995; Orlova et al., 2007; Santilli et al., 2009; Schmidt et al., 2000; Yan et al., 1996) (Figure 2). The ligand binding to RAGE activates multiple signaling pathways, such as ERK, STAT3, MAPK, and JNK that result in the augmentation of transcription factors, including nuclear factor kappa B (NF-kB) (Fritz, 2011; Klerdorf & Fritz, 2013) (Figure 1b). These ligand-RAGE interactions are primarily involved in the pathogenesis of various inflammatory diseases such as atherosclerosis, diabetes mellitus, cancer, neurodegenerative disorders (Alzheimer’s disease), rheumatoid arthritis, and chronic renal failure (Basta, 2008; Hofmann et al., 2002; Ramasamy et al., 2005; Rong et al., 2005; Schmidt et al., 1999; Schmidt et al., 2001; Taguchi et al., 2000; Tanji et al., 2000). Various extracellular and intracellular ligands that can bind to RAGE along with their clinical implications and binding sites on RAGE are summarized in Table 1.

3 | RAGE INHIBITORS

3.1 Small inhibitors that bind to extracellular domain of RAGE to inhibit the interactions with its extracellular ligands

The inhibition of ligand binding to RAGE is the best approach to attenuate the pathology of RAGE-mediated inflammation in various disease conditions. As summarized in Table 1, majority of the ligand activators of RAGE bind to the extracellular domain (V-domain). Several research groups published synthetic molecules to inhibit the interactions between RAGE and its ligands to treat various disease conditions. Among them, small inhibitors which were published before 2017 have already been summarized (Bongarzone et al., 2017). In this article, we summarized the small RAGE inhibitors published within the period of 2017–2021, along with their pharmacology, structure-activity relationship, and the available information on the binding mechanism with RAGE. Some key molecules having exemplary potential to inhibit RAGE that could treat RAGE-associated diseases published before 2017 are also described in this article with the new findings.

A very good example of RAGE inhibitor is FPS-ZM1 (compound 1), that was found by screening the 5000 compounds that can block the interactions between RAGE V-domain and Aβ1–42 to treat Alzheimer’s disease (Deane et al., 2012) (Figure 3). It can also inhibit the extracellular domain of RAGE from binding HMGB1 and S100B with the Ki (dissociation constant values) of 148 nM and 230 nM, respectively (Deane et al., 2012). FPS-ZM1 inhibits the activation of primary microglia by AGEs, and leads to decrease in the expression if RAGE, oxidative stress and thus lowers the level of inflammation (Shen et al., 2017). Recently, it has also been revealed that FPZ-ZM1 also alleviates the renal injury in hypertensive rats through RAGE inhibition (Liu et al., 2020). FPS-ZM1 has the perfect structural features that are mainly associated with RAGE binding. Its benzyl group attached directly to the amide nitrogen atom provides the electron-rich environment to its terminal group (benzyl group). Its tertiary amide central core provides the hydrogen-bond accepting and donating ability with amino acid residues present within the V-domain of RAGE. The electron deficient benzene ring attached to carbonyl carbon atom and six-membered acrylic chain of FPS-ZM1 provides the stability within the V-domain of RAGE. Its fluorine-18 (radiolabeled) analog (compound 2) was developed for imaging purposes for in vivo studies to trace RAGE which have excellent binding affinity with RAGE V-domain (Kd = 15 nM) (Cary et al., 2016) (Figure 3). This compound showed co-localization with RAGE in the brain samples of Alzheimer’s disease when tested through immunohistochemistry. It has superior central nervous system (CNS) penetration and increased uptake in several areas of the brain which are known to express RAGE than its parent analog FPS-ZM1. The binding modes of compound 2 were streamlined by using docking studies which are stabilized in the V-domain of RAGE via various hydrophobic interactions with Pro45, Leu49, Trp51, Pro66, Leu78, and Pro80 (Cary et al., 2016).
### Table 1 Various extracellular and intracellular RAGE binding ligands with their clinical implications

| Ligand | Type          | Binding domain | Binding affinity | Clinical implication                                                                 | References                                                                 |
|--------|---------------|----------------|------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| AGEs (MG-H1) | Extracellular ligand | V              | ND               | Cardiovascular diseases (atherosclerosis), Diabetes, cancer, chronic inflammation       | (Heier et al., 2015; Wetzels et al., 2019; Xue et al., 2011; Yamagishi, 2019) |
| S100B | Extracellular ligand | VC1             | 3.2–9.4 μM (ITC) | Inflammatory response and Neuronal disease, Down syndrome, Alzheimer’s disease.         | (Chen et al., 2020; Dattilo et al., 2007; Esposito et al., 2008)            |
|        |               | VC1             | $K_d = 11$ nM, $K_d = 244$ nM (SPR) |                                                |                                                                            |
|        |               | V               | $K_d = 550$ nM, $K_d = 470$ nM (SPR) |                                                |                                                                            |
| S100P | Extracellular ligand | V              | 6 μM             | Cancer disease and chronic inflammation                                                 | (Penumutchu et al., 2014; Lin et al., 2021)                                |
| S100A6 | Extracellular ligand | VC1             | 0.6–5.8 μM       | Alzheimer’s disease (AD), epileptogenesis, amyotrophic lateral sclerosis (ALS), Huntington’s disease (HD), and Parkinson's disease (PD) | (Filipek & Lesniak, 2020; Lederc et al., 2007)                             |
|        |               | V              | 0.5–13.5 μM      |                                                                                         |                                                                            |
|        |               | C2             | 28 nM to 1 μM    |                                                                                         |                                                                            |
| S100A11 | Extracellular ligand | V              | 0.5 μM (Immunofluorescence assay) | Cancer, Neurological diseases, Vascular calcification, and inflammatory diseases. | (Zhang et al., 2021; Huang et al., 2016)                                    |
| S100A12 | Extracellular ligand | C1              | 70 nM            | Cardiovascular diseases, Inflammatory response, and cancer progression                   | (Chiou et al., 2016; Saito et al., 2012; Wang et al., 2020; Xie et al., 2007) |
|        |               | V              | 3.1 μM (Immunofluorescence assay) |                                                                                         |                                                                            |
| Amyloid-β | Extracellular ligand | V & C1         | 70–90 nM         | Neurodegenerative disorders (Alzheimer's disease)                                        | (Deane et al., 2012)                                                      |
| Quinolinic acid | Extracellular ligand | VC1             | 43 nM            | Huntington’s disease, hepatic encephalopathy, AIDS-dementia complex, and Alzheimer’s disease | (Schwarz et al., 2012; Serratos et al., 2015)                               |
| HMGB1 | Extracellular ligand | VC1C2           | 6–10 nM          | Chronic inflammation and cancer                                                         | (Hori et al., 1995; Sims et al., 2010)                                     |
| DNA/RNA | Extracellular ligand | VC1             | ND               | Chronic inflammation                                                                     | (Siros et al., 2013)                                                      |
| RSV F-protein | Extracellular ligand | VC1             | Very low binding (Alpha Screen assay) | Modulates lower respiratory tract infection                                               | (Tian et al., 2013)                                                      |
| Longistatin | Extracellular ligand | V              | 72 nM            | Acts as an antagonist and can reduce the inflammation                                    | (Anisuzzaman et al., 2014)                                                 |
| TIRAP | Intracellular ligand | Cytoplasmic domain | ND               | Chronic inflammation                                                                     | (Rajpoot et al., 2021)                                                    |
| DIAPH1 | Intracellular ligand | Cytoplasmic domain | 4–8 μM           | Diabetes, cardiovascular diseases                                                       | (Egana-Gorroño et al., 2020; Rai et al., 2012)                             |
| ERK1/2 | Intracellular ligand | Cytoplasmic domain | ND                | Cancer and chronic inflammation                                                          | (Ishihara et al., 2003)                                                   |
| DOCK7 | Intracellular ligand | Cytoplasmic domain | ND                | Cancer and chronic inflammation                                                          | (Yamamoto et al., 2013)                                                   |
| C1q | Unknown       | Unknown         | ND                | Recruitment of phagocytosis                                                              | (Ma et al., 2012)                                                        |
| PS | Unknown       | Unknown         | ND                | Alveolar macrophagic Rac1 activation                                                     | (He et al., 2011)                                                        |

Abbreviation: RAGE, receptor for advanced glycation end products.
Another example of RAGE antagonist is the small molecule azeliragon (3), also known as PF-04494700. This molecule has been reported to inhibit the interactions of RAGE with extracellular ligands including S100B, HMGB1, and AGEs (Sabbagh et al., 2011) (Figure 3). Additionally, compound 3 was also found to inhibit the binding of extracellular domain of RAGE to Aβ1-42 with the IC₅₀ value of 500 nM which was determined by fluorescence polarization assay (Jones et al., 2012; Mjalli et al., 2009). The compound 3 reduced the neuroinflammation by reducing the level of Aβ1-42 plaque deposition and level of inflammatory cytokines (Burstein et al., 2018). Unfortunately, one clinical study revealed that compound 3 did not appear to exhibit consistent effect on the plasma levels of Aβ1-42 and inflammatory biomarkers (Burstein et al., 2014) and failed in the phase III study to treat the Alzheimer’s disease (“2-Year Extension Study of Azeliragon in Subjects With Alzheimer’s Disease (STEADFAST Extension),” 2021; “Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer’s Disease”, 2021). Moreover, the mechanism of binding of compound 3 with RAGE remains ambiguous as no structural data are available to establish their binding modes and locations. However, molecular docking studies performed by Xie et al. provide some basic notions of its binding mode with RAGE V-domain (Xie et al., 2021) and they used this information to further design novel RAGE inhibitors by modifying the central structural moiety of azeliragon i.e., imidazole to triazole. They synthesized the designed compounds and tested them to check their anticancer potential against triple-negative breast cancer cell line (TNBC) which is the most aggressive breast cancer cell line. Amongst all the compounds, compound 4 was found to be endowed with the best inhibitory potential against TNBC cells with the IC₅₀ value of 0.220 µM (Xie et al., 2021) (Figure 3).

Tranilast (compound 5) is an anti-allergic drug molecule that significantly inhibits the binding interactions of V-domain of RAGE with S100A11 and S100A12 which was tested using proton and nitrogen NMR titrations, fluorescence experiments, and WST-1 assay (Chiou et al., 2016; Huang et al., 2016) (Figure 3). Different interacting amino acids present in the active domain (V-domain) of RAGE with tranilast were also revealed using high ambiguity-driven biomolecular docking (HADDOCK). These results provide the mechanistic details of tranilast which could further be used for the development of novel RAGE inhibitors. Similarly, papaverine (a dimethoxy substituted isoquinoline derivative 6) was found to significantly inhibit the RAGE-dependent nuclear factor κ-B (NF-κB) activation driven by high mobility group box-1 (HMGB1) (El-Far et al., 2018) (Figure 3). C6 glioma cells were used to check the effect of papaverine on HMGB1-induced NF-κB activation. Papaverine (compound 6) at 10 and 20 µM concentration successively inhibited this upregulation. To evaluate the binding mechanism of papaverine with RAGE, AGE-RAGE binding assay was performed which revealed that the papaverine can bind to the binding site of AGE (i.e., V-domain of RAGE) (El-Far et al., 2018). The amino acids of V-domain of RAGE involved in these interactions are still unknown. Recent studies stated that papaverine also can suppress the chronic inflammatory pain in mice model, while it did not show the anti-nociceptive effects in the state of oxidative stress at the site of inflammation (Yoshizawa et al., 2021). Therefore, papaverine and its derivatives could act as lead molecules in the development of novel potent RAGE antagonist that can be used to treat various RAGE-associated diseases.

In 2019, Ahmad et al. (2019) claimed a natural molecule emetine (compound 7) as a potent inhibitor of RAGE and Aβ1-42 interactions which was confirmed through computational studies (Figure 3). Compound 7 itself can bind efficiently with Aβ1-42 with the calculated energy −6.99 kcal/Mol but was found to interact with the same amino acid residues of Aβ1-42 which are responsible for binding with RAGE V-domain (Ahmad et al., 2019), which suggests that emetine
(compound 7) could be the novel invention for the further development of anti-Alzheimer’s agents that affect the RAGE signaling pathway. The actual potential of compound 7 to inhibit these interactions are experimentally unproven. Similarly, aminopyrimidine derivatives and phenyl benzoxazoles derivatives discovered a few years back (structures are not provided) were also found to show excellent inhibition in the interactions of RAGE and Aβ1-42 with the potential to treat AD, however the actual binding mechanism was not predicted (Choi et al., 2015; Han et al., 2012). Recently, Kozlyuk et al. applied a fragment-based approach to develop new RAGE inhibitors that can specifically directed to its ligand-binding domain (VC1-domain) (Kozlyuk et al., 2021). They screened binding of around 14,000 small fragments with RAGE V-domain initially through chemical shift perturbations (CSPs) in the nuclear magnetic resonance (NMR) spectra. The lead fragments were further used to develop the X-ray co-crystallized structure with RAGE V and C1 domains to evaluate their exact location and orientation. In this way they identified three best binders (compounds 8–10) that can bind to three alternative sites on RAGE receptor (Kozlyuk et al., 2021) (Figure 3).

Figure 4 describes the available binding sites on the RAGE receptor (extracellular domain) with their amino acid residues and orientation of compounds 8–10 within their specific sites. The X-ray co-crystallized structure of these compounds with RAGE receptor have also been published in protein data bank with PDB codes 6xq5 (binding site 1), 6xq6 (binding site 2), and 6xq3 (binding site 3) (Kozlyuk et al., 2021). To the best of our knowledge, before this study, there was no crystallographic data available of RAGE with its bound inhibitors, so it is worth schematically representing the RAGE with its bound ligands at different sites which could be useful for structure elucidation of novel RAGE binders in future studies. A major limitation of the study was the lack of data on direct inhibition of RAGE signaling. However, these results, combined with the crystal structures of three compounds, can be successfully used to further develop novel RAGE specific inhibitors.

3.2 Small molecule inhibitors of RAGE that can bind intracellularly

The intracellular domain of RAGE is also critically responsible for various types of RAGE signaling and downstream effects. Blocking the interactions between RAGE and mammalian DIAPH1 provide therapeutic value to treat RAGE-mediated chronic inflammatory conditions. Manigrasso et al. identified thirteen best small molecules (compounds 11–23) amongst a set of 58,000 molecules that can bind to the cytoplasmic domain and inhibit the binding of RAGE and DIAPH1 (Manigrasso et al., 2016) (Figure 5a). All these compounds showed binding affinity with cytoplasmic domain of RAGE with dissociation constants ranging from 0.3 to 32 nM, among which compound 16 exhibited excellent affinity (0.3 nM) with RAGE (Figure 5a). NMR spectroscopy was performed to corroborate binding affinities with RAGE cytoplasmic domain. Careful examination of structural features of these compounds revealed that some compounds consisted of hydrophobic or aliphatic moieties with central amide linker (compounds 11, 16, 17, 22, & 23) that may be responsible for hydrogen-bonding interactions with RAGE cytoplasmic tail. Some compounds bearing the terminal benzimidazole moieties (compounds 13, 14, & 19), the nitrogen atoms can be involved in accepting and donating the hydrogen bonds between the
amino acid residues of cytoplasmic tail of RAGE (Figure 5a). RAGE-DIAPH1-dependent molecular processes were significantly halted by these molecules which are mainly associated with various disease conditions such as diabetes, Alzheimer’s disease, and chronic inflammation (Manigrasso et al., 2016).

### 3.3 | Small molecule inhibitors of RAGE with unknown binding mechanisms

A thiazolidinone-based drug molecule, that is, pioglitazone (compound 24), a potent PPAR-γ agonist, is also proven to be a RAGE antagonist, the administration of which significantly reduced the size of atherosclerotic plaque in diabetic ApoE−/− mice (Gao et al., 2017). In high glucose treated VSMCs, compound 24 also downregulated the protein as well as mRNA expression of RAGE (Figure 5b). The mechanism of the binding of compound 24 with RAGE domains is unclear. Gliclazide (a known antidiabetic drug; compound 25) has also been reported to abate the AGE-RAGE pathway to treat the diabetic atherosclerosis (Jahan & Choudhary, 2021) (Figure 5b). As the study revealed gliclazide (1–100 µM) attenuated the cytokines production including IL-1β, IL-6, and TNF-α in concentration-dependent manner in RAW 264.7 macrophages and can also induce the production of anti-inflammatory cytokines (IL-10 and TGF-β) (Jahan & Choudhary, 2021). However, the study does not reveal the underlying mechanism of the inhibition of AGE-RAGE signaling by gliclazide.

![Figure 5](image-url)

**Figure 5** (a) Molecular structure of various RAGE inhibitors that bind to its intracellular domain; (b) Structure of RAGE inhibitors with unknown mechanism. RAGE, receptor for advanced glycation end products

### 4 | LATEST DEVELOPMENT IN THE FIELD OF RAGE AND ITS INHIBITORS

RAGE is the immunoglobulin family receptor which is present on most cell types and have been reported to involve in various inflammatory conditions such as cardiovascular diseases, neurodegeneration, cancer, and diabetes. RAGE can interact with several endogenous and exogenous ligands to initiate the downstream signaling that leads to chronic inflammatory conditions. Targeting RAGE and its interactions with other ligands by using various inhibitors could be a potential therapeutic treatment of these diseases. Accordingly, small inhibitors have been developed in recent years to target the extracellular and intracellular ligand binding sites of RAGE to block downstream signaling pathways. The inhibitors described in this compilation confirmed that RAGE inhibition could be a powerful approach toward the management of immune-inflammatory diseases. The compounds in this article may act as scaffolds for further chemical refinement and optimization toward the activity, selectivity, and pharmacokinetics that could lead to future success in the management of RAGE-associated diseases. Following the discovery and understanding of the signaling potential of RAGE, research has mainly been diverted towards the correlation between its activity and various pathological conditions including cardiovascular diseases, Alzheimer’s disease, cancer, and diabetes. RAGE has become an attractive therapeutic target that can be inhibited through its extracellular and intracellular domains. So far, binding models for
the interaction of RAGE with various ligands such as AGEs, S100A6, S100A11, S100A12, S100B, S100P, and DIAPH1 have been developed. However, the mechanism of binding of quinolinic acid, Aβ1-42, HMGB1, TIRAP, ERK, and DOCK7 with RAGE is still unknown. Some molecules enhance the level of soluble RAGE (sRAGE) which may act as modulators of RAGE-mediated pathways, as sRAGE has been investigated as a scavenger of its ligands to reduce their accumulation at the site of injury in organs (Emanuele et al., 2005; Falcone et al., 2005). However, sRAGE could not be an ideal therapeutic agent to target RAGE because of its large size (large recombinant protein of 36.5 kDa) and thus difficult to produce at the therapeutic level. Therefore, there is a pressing need to develop small molecule inhibitors of RAGE that could be useful in the treatment of RAGE-associated diseases. Recently, various research groups reported small molecules that can inhibit interactions of RAGE with its ligands extracellularly or intracellularly. Such molecules may prove effective in reducing the activation of downstream signaling of RAGE to treat various disease conditions. Till 2020, three putative binding sites have been described only through molecular modeling studies or homology modeling. Later in the middle of year 2021, it was confirmed by obtaining the X-ray co-crystallized structures of RAGE with bound small molecules (compounds 8–10). This clearly depicted three binding sites on the RAGE extracellular domain (VC1), supporting the previous molecular docking data (Kozlyuk et al., 2021) (Figure 4). NMR data have also been generated corroborating the actual binding of these molecules with RAGE extracellular domain (Kozlyuk et al., 2021). The co-crystallized structures of RAGE with these molecules may not only lead to improve the understanding of orientation of active pockets on the extracellular domain but would also expedite the discovery of specific and potent RAGE antagonist in future. These complexes would be crucial for the generation of novel RAGE chemotypes and drug like molecules using structure-guided drug designing approach.

5 | CONCLUSION

Critical findings in the literature revealed that FPS-ZM1 (compound 1; Figure 3) still has the greatest potential in this field of research to treat various inflammatory conditions by acting as potent RAGE antagonist. FPS-ZM1 has acceptable blood-brain barrier permeability and disrupt RAGE-Aβ1-42 interactions with profound toxicological profile in cell culture and rodent models (Shen et al., 2017). Its Fluorine (18F) radiolabeled analog compound 2 (Figure 3) can potently bind to RAGE and thus used to quantify the CNS RAGE in the in vivo models (Cary et al., 2016). However, this compound still needs further in vivo characterization to demonstrate its applicability in actual clinical studies which can justify whether it could be useful in the treatment of neurological disorders or not. From the discovery of co-crystallized structure of RAGE with bound ligand (Figure 4), it can be assumed that both compounds FPS-ZM1 and its analog (compound 2) can potently bind to the site 3 of RAGE VC1 domain, as indicated by their previous molecular docking data. In addition to these potent RAGE antagonists, papaverine (compound 6; Figure 3) has also been reported to target the RAGE to further attenuate its downstream signaling through blocking the interactions of RAGE with AGEs, which could be useful in the treatment of AGE-RAGE-associated inflammatory disease conditions. However, comparatively higher dose of compounds 1 or 2 to inhibit these interactions could limit their clinical use as a RAGE antagonist (El-Far et al., 2018). Besides extracellular small molecule inhibitors, molecules 11–23 (Figure 5a) that can target intracellular RAGE have also been reported with excellent binding affinities towards the RAGE intracellular domain (Manigrasso et al., 2016). These molecules inhibit the interactions between the intracellular ligand DIAPH1 with RAGE which can ultimately attenuate further signaling processes associated with various disease conditions. The inhibitors described in this compilation support that RAGE inhibition could be a powerful approach to the management of immune-inflammatory diseases. A critical review of the literature suggests further investigations to look deeper into their molecular mechanism of action and to better understand the efficacy of RAGE-targeting therapy and long-term blockade of RAGE in humans.

ACKNOWLEDGMENTS

The research work of DK Agrawal is supported by research grants R01 HL144125 and R01HL147662 from the National Institutes of Health, USA. The content of this review article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

Not applicable; all information is gathered from published articles.

DISCLOSURES

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

ORCID

Harbinder Singh  http://orcid.org/0000-0002-1949-2143
Devendra K. Agrawal  http://orcid.org/0000-0001-5445-0013

REFERENCES

Adrover, M., Marino, L., Sanchis, P., Pauwels, K., Kraan, Y., Lebrun, P., & Donoso, J. (2014). Mechanistic insights in glycation-induced protein aggregation. Biomacromolecules, 15(9), 3449–3462. https://doi.org/10.1021/bm501077j
Ahmad, S. S., Khan, H., Danish Rizvi, S. M., Ansari, S. A., Ullah, R., Rastrelli, L., & Siddiqui, M. H. (2019). Compositional study of natural compounds for the clearance of amyloid-beta: A potential therapeutic management strategy for Alzheimer's disease. Molecules, 24(18). https://doi.org/10.3390/molecules24183233
Akhter, F., Khan, M. S., & Ahmad, S. (2015). Acquired immunogenicity of calf thymus DNA and LDL modified by d-ribose: A comparative study. International Journal of Biological Macromolecules, 72, 1222–1227. https://doi.org/10.1016/j.ijbiomac.2014.10.034
Aniszuzzaman, Hatta, T., Miyoshi, T., Matsubayashi, M., Islam, M. K., Alim, M. A., & Tsuji, N. (2014). Longistatin in tick saliva blocks advanced glycation end-product receptor activation. Journal of Clinical Investigation, 124(10), 4429–4444. https://doi.org/10.1172/jci74917

Basta, G. (2008). Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis, 194(1), 9–21. https://doi.org/10.1016/j.atherosclerosis.2007.07.025

Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., & Nawroth, P. P. (2005). Understanding RAGE, the receptor for advanced glycation end products. Journal of Molecular Medicine, 83(11), 876–886. https://doi.org/10.1007/s00109-005-0688-7

Bongarzone, S., Savickas, V., Luzi, F., & Gee, A. D. (2017). Targeting the receptor for advanced glycation end products (RAGE): A medicinal chemistry perspective. Journal of Medicinal Chemistry, 60(17), 7213–7232. https://doi.org/10.1021/acs.jmedchem.7b00058

Brett, J., Schmidt, A. M., Yan, S. D., Zou, Y. S., Weidman, E., Pinskiy, D., Nowygrod, R., Neeper, M., Przysecki, C., Shaw, A., Migheli, A., & Stern, D. (1993). Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. American Journal of Pathology, 143(6), 1699–1712. https://www.ncbi.nlm.nih.gov/pubmed/8285657

Burstein, A. H., Grimes, I., Galasko, D. R., Aisen, P. S., Sabbagh, M., & MJalli, A. M. (2014). Effect of TTP488 in patients with mild to moderate Alzheimer’s disease. BMC Neurology, 14, 12. https://doi.org/10.1186/1471-2377-14-12

Burstein, A. H., Sabbagh, M., Andrews, R., Valcarce, C., Dunn, I., & Altstiel, L. (2018). Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer’s disease. Journal of Prevention of Alzheimer’s Disease, 5(2), 149–154. https://doi.org/10.14283/jpad.2018.18

Cary, B. P., Brooks, A. F., Fawaz, M. V., Drake, L. R., Desmond, T. J., Sherman, P., & Scott, P. J. (2016). Synthesis and evaluation of [(18)F] RAGER: A first generation small-molecule PET radioligand targeting the receptor for advanced glycation endproducts. ACS Chemical Neuroscience, 7(3), 391–398. https://doi.org/10.1021/acschemneuro.5b00319

Chavakis, T., Bierhaus, A., Al-Fakhrni, N., Schneider, D., Witte, S., Linn, T., & Nawroth, P. P. (2003). The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: A novel pathway for inflammatory cell recruitment. Journal of Experimental Medicine, 198(10), 1507–1515. https://doi.org/10.1084/jem.20030800

Chen, C., Jiang, P., Xue, H., Peterson, S. E., Tran, H. T., McCann, A. E., & Deng, W. (2020). Author correction: Role of astroglia in Down’s syndrome neural progenitors implicates S100B and aquaporin 4 in cell injury. Human Molecular Genetics, 17(3), 440–457. https://doi.org/10.1093/hmg/ddm322

Falcone, C., Emanuele, E., D’Angelo, A., Buze, M. P., Belvito, C., Cuccia, M., & Geroldi, D. (2005). Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(3), 1032–1037. https://doi.org/10.1161/01.ATV.0000160342.20342.00

Filipek, A., & Lesniak, W. (2020). S100A6 and its brain ligands in neurodegenerative disorders. International Journal of Molecular Sciences, 21(11). https://doi.org/10.3390/ijms21113797

Fritz, G. (2011). RAGE: A single receptor fits multiple ligands. Trends in Biochemical Sciences, 36(12), 625–632. https://doi.org/10.1016/j.tibs.2011.08.008

Gao, H., Li, H., Li, W., Shen, X., & Di, B. (2017). Pioglitazone attenuates atherosclerosis in diabetic mice by inhibition of receptor for advanced glycation end-product (RAGE) signaling. Medical Science Monitor, 23, 6121–6131. https://doi.org/10.12659/msm.907401

Geroldi, D., Falcone, C., & Emanuele, E. (2006). Soluble receptor for advanced glycation end products: From disease marker to potential therapeutic target. Current Medicinal Chemistry, 13(17), 1971–1978. https://doi.org/10.2174/09298670677585013

Han, Y. T., Choi, G. I., Son, D., Kim, N. J., Yun, H., Lee, S., & Suh, Y. G. (2012). Ligand-based design, synthesis, and biological evaluation of 2-aminopyrimidines, a novel series of receptor for advanced
glycation end products (RAGE) inhibitors. *Journal of Medicinal Chemistry*, 53(21), 9120–9135. https://doi.org/10.1021/jm300172z

He, M., Kubo, H., Morimoto, K., Fujino, N., Suzuki, T., Takahasi, T., & Yamamoto, H. (2011). Receptor for advanced glycation end products binds to phosphatidylserine and assists in the clearance of apoptotic cells. *EMBO Reports*, 12(4), 358–364. https://doi.org/10.1038/embob.2011.28

Heier, M., Margeirdottir, H. D., Torjesen, P. A., Seljeflot, I., Stensaeth, K. H., Gaarder, M., & Dahl-Jorgensen, K. (2015). The advanced glycation end product methylglyoxal-derived hexosimidoazolone-1 and early signs of atherosclerosis in childhood diabetes. *Diabetes & Vascular Disease Research*, 12(2), 139–145. https://doi.org/10.1177/147916 4115069109

Hofmann, M. A., Drury, S., Fu, C., Qu, W., Taguchi, A., Lu, Y., & Schmidt, A. M. (1999). RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides. *Cell*, 9(7), 889–901. https://doi.org/10.1016/s0092-8674(00)80801-6

Hofmann, M. A., Drury, S., Hudson, B. I., Gleason, M. R., Qu, W., Lu, Y., & Schmidt, A. M. (2002). RAGE and arthritis: The G82S polymorphism amplifies the inflammatory response. *Genes and Immunity*, 3(3), 123–135. https://doi.org/10.1038/sj.gi.6363861

Hong, Y., Shen, C., Yin, Q., Sun, M., Ma, Y., & Liu, X. (2016). Effects of RAGE-Specific inhibitor FFS-ZM1 on amyloid-beta metabolism and AGEs-induced inflammation and oxidative stress in rat hippocampus. *Neurochemical Research*, 41(5), 1192–1199. https://doi.org/10.1007/s11064-015-1814-8

Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., Morser, J., Stem, D., & Schmidt, A. M. (1995). The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphetamine. Mediation of neutrie outgrowth and co-expression of rage and amphetamine in the developing nervous system. *Journal of Biological Chemistry*, 270(43), 25752–25761. https://doi.org/10.1074/jbc.270.43.25752

Huang, Y. K., Chou, R. H., & Yu, C. (2016). Tranilast blocks the interaction between the protein S100A11 and receptor for advanced glycation end products (RAGE) V domain and inhibits cell proliferation. *Journal of Biological Chemistry*, 291(27), 14300–14310. https://doi.org/10.1074/jbc.M116.722215

Hudson, B. I., & Lippman, M. E. (2018). Targeting RAGE signaling in inflammatory disease. *Annual Review of Medicine*, 69, 349–364. https://doi.org/10.1146/annurev-med-041316-085215

Hudson, B. I., Kalea, A. Z., Del Mar Arriero, M., Harja, E., Boulanger, E., Jabir, N. R., Ahmad, S., & Tabrez, S. (2018). An insight on the association of glycation end products (RAGE) inhibitors. *PLoS One*, 8(11), e78267. https://doi.org/10.1371/journal.pone.0078267

Kalea, A. Z., Schmidt, A. M., & Hudson, B. I. (2009). RAGE: A novel biological and genetic marker for vascular disease. *Clin Sci (Lond)*, 116(8), 621–637. https://doi.org/10.1042/CS20080494

Katsuoka, F., Kawakami, Y., Arai, T., Imuta, H., Fujiwara, M., Kann, H., & Yamashita, K. (1997). Type II alveolar epithelial cells in lung express receptor for advanced glycation end products (RAGE) gene. *Biochemical and Biophysical Research Communications*, 238(2), 512–516. https://doi.org/10.1016/S0006-291X(97)7263

Kierdorf, K., & Fritz, G. (2013). RAGE regulation and signaling in inflammation and beyond. *Journal of Leukocyte Biology*, 9(1), 55–68. https://doi.org/10.1189/jlb.1012519

Koch, M., Chitayat, S., Dattilo, B. M., Schieffer, A., Diez, J., Chazin, W. J., & Fritz, G. (2010). Structural basis for ligand recognition and activation of RAGE. *Structure*, 18(10), 1342–1352. https://doi.org/10.1016/j.str.2010.05.017

Kosaka, T., Fukui, R., Matsui, M., Kurosaka, Y., Nishimura, H., Tanabe, M., & Fujita, T. (2014). RAGE, receptor of advanced glycation endproducts, negatively regulates chondrocytes differentiation. *PLoS One*, 9(9), e108819. https://doi.org/10.1371/journal.pone.0108819

Kozyuk, N., Gilston, B. A., Salay, L. E., Gogliotti, R. D., Christov, P. P., Kim, K., & Chazin, W. J. (2021). A fragment-based approach to discovery of receptor for advanced glycation end products inhibitors. *Proteins*, 89(11), 1399–1412. https://doi.org/10.1002/prot.26162

Leclerc, E., Fritz, G., Weibel, M., Heizmann, C. W., & Galichet, A. (2007). S100B and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. *Journal of Biological Chemistry*, 282(43), 31317–31331. https://doi.org/10.1074/jbc.M703951200

Li, J., Liu, D., Sun, L., Lu, Y., & Zhang, Z. (2012). Advanced glycation end products and neurodegenerative diseases: Mechanisms and perspective. *Journal of the Neurological Sciences*, 317(1-2), 1–5. https://doi.org/10.1016/j.jns.2012.02.018

Lin, L., Park, S., & Lakatta, E. G. (2009). RAGE signaling in inflammation and arterial aging. *Frontiers of Bioscience (Landmark Ed)*, 14(4), 1403–1413. https://doi.org/10.2741/3315

Lin, M., Fang, Y., Li, Z., Li, Y., Feng, X., Zhan, Y., & Deng, H. (2021). S100P contributes to promoter demethylation and transcriptional activation of SLC2A5 to promote metastasis in colorectal cancer. *British Journal of Cancer*, 125(5), 734–747. https://doi.org/10.1038/s41 461-021-01306-2

Liu, Y., Shen, W., Chen, Q., Cao, Q., Di, W., Lan, R., & Xu, W. (2020). Inhibition of RAGE by FFS-ZM1 alleviates renal injury in spontaneously hypertensive rats. *European Journal of Pharmacology*, 882, 173228. https://doi.org/10.1016/j.ejphar.2020.173228

Logidon, C. D., Fuentes, M. K., Huang, E. H., & Arumugam, T. (2007). RAGE and RAGE ligands in cancer. *Current Molecular Medicine*, 7(8), 777–789. https://doi.org/10.2174/156562407783220697

Ma, W., Rai, V., Hudson, B. I., Song, F., Schmidt, A. M., & Barile, G. R. (2012). RAGE binds C1q and enhances C1q-mediated phagocytosis. *Cellular Immunology*, 274(1-2), 72–82. https://doi.org/10.1016/j.cellimm.2012.02.001

Manigrasso, M. B., Pan, J., Rai, V., Zhang, J., Reverdatto, S., Quadri, N., & Schmidt, A. M. (2016). Small molecule inhibition of ligand-stimulated RAGE-DIAPH1 signal transduction. *Scientific Reports*, 6, 22450. https://doi.org/10.1038/srep22450

Mjall, A. M. M., Andrews, R. C., Shen, J. M., & Rothlein, R. (2009). RAGE antagonists as agents to reverse amyloidosis and diseases associated therewith (Patent # WO20120000295).

Nabi, R., Alvi, S. S., Shah, A., Chaturvedi, C. P., Iqbal, D., Ahmad, S., & Khan, M. S. (2019). Modulatory role of HMG-CoA reductase inhibitors and ezetimibe on LDL-AGEs-induced ROS generation.
and RAGE-associated signalling in HEK-293 cells. Life Sciences, 235, 116823. https://doi.org/10.1016/j.lfs.2019.116823

Nasser, M. W., Wani, N. A., Ahirwar, D. K., Powell, C. A., Ravi, J., Elbaz, M., & Ganju, R. K. (2015). RAGE mediates S100A7-induced breast cancer growth and metastasis by modulating the tumor microenvironment. Cancer Research, 75(6), 974–985. https://doi.org/10.1158/0008-5472.CAN-14-2161

Neeper, M., Schmidt, A. M., Brett, J., Yan, S. D., Wang, F., Pan, Y. C., & Shaw, A. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. Journal of Biological Chemistry, 267(21), 14998–15004. https://www.ncbi.nlm.nih.gov/pubmed/1378843

Nenova, A., Spadaccio, C., Lusini, M., Ulianich, L., Chello, M., & Nappi, F. (2015). Basic and clinical research against advanced glycation end products (AGEs): New compounds to tackle cardiovascular disease and diabetic complications. Recent Advances in Cardiovascular Drug Discovery, 10(1), 10–33. https://doi.org/10.2174/15748901010661611004120039

Ozcyk, E. A., Perkins, T. N., & Oury, T. D. (2017). All the structure of C-receptor for advanced glycation end products (RAGE): Solution to disorders of the nervous system. Diabetes and Associated Disorders, 25(3), 206–212. https://doi.org/10.1097/WAD.0b013e318204b550

Saito, T., Hojo, Y., Ogoyama, Y., Hirose, M., Ikemoto, T., Katsuki, T., & Kario, K. (2012). S100A12 as a marker to predict cardiovascular events in patients with chronic coronary artery disease. Circulation Journal, 76(11), 2647–2652. https://doi.org/10.1253/circj-cj-12-0093

Sajithlal, G. B., Chithra, P., & Chandrakasan, G. (1998). Advanced glycation end products induce crosslinking of collagen in vitro. Biochimica et Biophysica Acta/General Subjects, 1407(3), 215–224. https://doi.org/10.1016/s0925-4439(98)00043-x

Santilli, F., Vazanna, N., Buccarelli, L. G., & Davi, G. (2009). Soluble forms of RAGE in human diseases: Clinical and therapeutic implications. Current Medicinal Chemistry, 16(8), 940–952. https://doi.org/10.2174/0929670977581888

Scavello, F., Zeni, F., Milano, G., Maci, F., Castiglione, S., Zuccolò, E., & Raucci, A. (2021). Soluble receptor for advanced glycation end-products regulates age-associated cardiac fibrosis. International Journal of Biological Sciences, 17(10), 2399–2416. https://doi.org/10.7150/ijbs.56379

Schmidt, A. M., Yan, S. D., Wautier, J. L., & Stern, D. (1999). Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circulation Research, 84(5), 489–497. https://doi.org/10.1161/01.res.84.5.489

Schmidt, A. M., Yan, S. D., Yan, S. F., & Stern, D. M. (2000). The biology of the receptor for advanced glycation end products and its ligands. Biochimica et Biophysica Acta/General Subjects, 1498(2-3), 99–111. https://doi.org/10.1016/s1574-4889(00)00087-2

Schmidt, A. M., Yan, S. D., Yan, S. F., & Stern, D. M. (2001). The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. Journal of Clinical Investigation, 108(7), 949–955. https://doi.org/10.1172/JCI14002

Schwarz, R., Bruno, J. P., Muchowski, P. J., & Wu, H. Q. (2012). Kynurenines in the mammalian brain: When physiology meets pathology. Nature Reviews Neuroscience, 13(7), 465–477. https://doi.org/10.1038/nrn3257

Serratos, I. N., Castellanos, P., Pastor, N., Millan-Pacheco, C., Rembao, D., Perez-Montfort, R., & Santamaria, A. (2015). Modeling the interaction between quinoline and the receptor for advanced glycation end products (RAGE). Relevance for early neuropathological processes. PLoS One, 10(3), e0120221. https://doi.org/10.1371/journal.pone.0120221

Shen, C., Ma, Y., Zeng, Z., Yin, Q., Hong, Y., Hou, X., & Liu, X. (2017). RAGE-Specific inhibitor FFS-ZM1 attenuates AGEs-induced neuroinflammation and oxidative stress in rat primary microglia. Neurochemical Research, 42(10), 2902–2911. https://doi.org/10.1007/s11064-017-2321-x

Sims, G. P., Rowe, D. C., Riedijk, S. T., Herbst, R., & Coyle, A. J. (2010). HMGBl and RAGE in inflammation and cancer. Annual Review of Immunology, 28, 367–388. https://doi.org/10.1146/annurev.immunol.021908.123203

Sirois, C. M., Jin, T., Miller, A. L., Berthelot, D., Nakamura, H., Horvath, G. L., & Latz, E. (2013). RAGE is a nucleic acid receptor that promotes inflammatory responses to DNA. Journal of Experimental Medicine, 210(11), 2447–2463. https://doi.org/10.1084/jem.20120201

Spavaro, L. J., Asafu-Adjei, D., Kang, R., Tang, D., Amin, N., Im, J., & Lotze, M. T. (2009). RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. Journal of Translational Medicine, 7, 17. https://doi.org/10.1186/1479-5876-7-17

Sturchler, E., Galichet, A., Weibel, M., Leclerc, E., & Heizmann, C. W. (2008). Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. Journal of Neuroscience, 28(20), 5149–5158. https://doi.org/10.1523/JNEUROSCI.4878-07.2008
Takeuchi, A., Yamamoto, Y., Munesue, S., Harashima, A., Watanabe, T., Xue, J., Rai, V., Singer, D., Chabierski, S., Xie, J., Reverdatto, S., & Shekhtman, A. (2011). Advanced glycation end product recognition by the receptor for AGES. Structure, 19(5), 722–732. https://doi.org/10.1016/j.str.2011.02.013

Xue, J., Ray, R., Singer, D., Bohme, D., Burz, D. S., Rai, V., & Shekhtman, A. (2014). The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGES. Biochemistry, 53(20), 3327–3335. https://doi.org/10.1021/bi500046t

Yamagishi, S. (2011). Role of advanced glycation end products (AGES) and receptor for AGES (RAGE) in vascular damage in diabetes. Experimental Gerontology, 46(4), 217–224. https://doi.org/10.1016/j.exger.2010.11.007

Yamagishi, S. I. (2019). Role of advanced glycation endproduct (AGE)-Receptor for advanced glycation end product (RAGE) axis in cardiovascular disease and its therapeutic intervention. Circulation Journal, 83(9), 1822–1828. https://doi.org/10.1253/circj.CJ-19-0618

Yamamoto, K., Murata, H., Putranto, E. W., Kataoka, K., Motoyama, A., Hibino, T., & Huh, N. H. (2013). DOCK7 is a critical regulator of the RAGE-Cd42 signaling axis that induces formation of dendritic pseudopodia in human cancer cells. Oncology Reports, 29(3), 1073–1079. https://doi.org/10.3892/or.2012.2191

Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., & Schmidt, A. M. (1996). RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature, 382(6593), 685–691. https://doi.org/10.1038/382685a0

Yatime, L., & Andersen, G. R. (2013). Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products. FEBS Journal, 280(24), 6556–6568. https://doi.org/10.1111/febs.12556

Yonemoto, K., Yamamoto, Y., Sakurai, S., Petrova, R. G., Abedin, M. J., Li, H., & Yamamoto, H. (2003). Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochemical Journal, 370(Pt 3), 1097–1109. https://doi.org/10.1042/BJ20021371

Yoshizawa, K., Takeuchi, K., Nakamura, T., Ukai, S., Takahashi, Y., Sato, A., & Tanuma, S. I. (2021). Antinociceptive activity of the novel RAGE inhibitor, papaverine, in a mouse model of chronic inflammatory pain. Synapse, 75(3), e22188. https://doi.org/10.1002/syn.e22188

Zhang, L., Zhi, T., Miao, H., & Liang, B. (2021). The calcium binding protein S100A11 and its roles in diseases. Frontiers in Cell and Developmental Biology, 9, 693262. https://doi.org/10.3389/fcell.2021.693262

Zhang, L., Bukulin, M., Kojro, E., Roth, A., Metz, V. V., Fahrenholz, F., & Postina, R. (2008). Receptor for advanced glycation end products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Journal of Biological Chemistry, 283(31), 35507–35516. https://doi.org/10.1074/jbc.M806948200

Zong, H., Madden, A., Ward, M., Mooney, M. H., Elliott, C. T., & Stitt, A. W. (2010). Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. Journal of Biological Chemistry, 285(30), 23137–23146. https://doi.org/10.1074/jbc.M110.133827

How to cite this article: Singh, H., & Agrawal, D. K. (2022). Therapeutic potential of targeting the receptor for advanced glycation end products (RAGE) by small molecule inhibitors. Drug Development Research, 83, 1257–1269. https://doi.org/10.1002/ddr.21971